Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard Scheiner

Showing results (11-20 of 203) with videos related to

Pageof 21
Sort By:
Journal of Hepatology|June 10, 2022
On coagulation in advanced chronic liver disease and the origin of freshwater eelsMattias Mandorfer, Bernhard Scheiner, Ton Lisman
Journal of Hepatology|February 6, 2022
Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfectionMathias Jachs, Bernhard Scheiner, Matthias Pinter
Alimentary Pharmacology & Therapeutics|July 4, 2024
Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease: Authors' replyBernhard Scheiner, Nina Dominik, Mattias Mandorfer
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2022
ReplyGeorg Semmler, Thomas Reiberger, Bernhard Scheiner
Gut|August 5, 2020
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroupsMatthias Pinter, Bernhard Scheiner, Markus Peck-Radosavljevic
Liver Cancer|February 20, 2020
Reply to the Letter to the Editor Entitled "Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?"Bernhard Scheiner, Martha M Kirstein, Matthias Pinter
The Lancet. Gastroenterology & Hepatology|June 16, 2023
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practiceMatthias Pinter, Bernhard Scheiner, David J Pinato
Liver International : Official Journal of the International Association for the Study of the Liver|October 30, 2025
Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated CirrhosisLorenzo Lani, Bernhard Scheiner, Matthias Pinter, et al.
Alimentary Pharmacology & Therapeutics|September 25, 2018
Editorial: surviving your genes-the role of PNPLA3 variation in end-stage liver disease. Authors' replyMattias Mandorfer, Bernhard Scheiner, Thomas Reiberger, et al.
Journal of Hepatology|February 22, 2023
Reply to: 'From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?'Bernhard Scheiner, Lorenz Balcar, Ton Lisman, et al.
Pageof 21

Showing results (11-20 of 203) with videos related to

Sort By:
Pageof 21
Journal of Hepatology|June 10, 2022
On coagulation in advanced chronic liver disease and the origin of freshwater eelsMattias Mandorfer, Bernhard Scheiner, Ton Lisman
Journal of Hepatology|February 6, 2022
Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfectionMathias Jachs, Bernhard Scheiner, Matthias Pinter
Alimentary Pharmacology & Therapeutics|July 4, 2024
Letter: Helicobacter pylori and metabolic syndrome-related von Willebrand factor and plasminogen activator inhibitor-1 activity levels for outcome prediction of advanced chronic liver disease: Authors' replyBernhard Scheiner, Nina Dominik, Mattias Mandorfer
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 16, 2022
ReplyGeorg Semmler, Thomas Reiberger, Bernhard Scheiner
Gut|August 5, 2020
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroupsMatthias Pinter, Bernhard Scheiner, Markus Peck-Radosavljevic
Liver Cancer|February 20, 2020
Reply to the Letter to the Editor Entitled "Too Many versus Too Few Platelets in Patients with Hepatocellular Carcinoma: Good or Bad?"Bernhard Scheiner, Martha M Kirstein, Matthias Pinter
The Lancet. Gastroenterology & Hepatology|June 16, 2023
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practiceMatthias Pinter, Bernhard Scheiner, David J Pinato
Liver International : Official Journal of the International Association for the Study of the Liver|October 30, 2025
Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated CirrhosisLorenzo Lani, Bernhard Scheiner, Matthias Pinter, et al.
Alimentary Pharmacology & Therapeutics|September 25, 2018
Editorial: surviving your genes-the role of PNPLA3 variation in end-stage liver disease. Authors' replyMattias Mandorfer, Bernhard Scheiner, Thomas Reiberger, et al.
Journal of Hepatology|February 22, 2023
Reply to: 'From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?'Bernhard Scheiner, Lorenz Balcar, Ton Lisman, et al.
Pageof 21